Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development.
about
Development and utility of an internal threshold control (ITC) real-time PCR assay for exogenous DNA detectionPCR-based detection of gene transfer vectors: application to gene doping surveillance.Engineering biomaterial systems to enhance viral vector gene delivery.Real-time quantitative PCR for the design of lentiviral vector analytical assays.Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responsesDistribution characteristics of DNA vaccine encoded with glycoprotein C from Anatid herpesvirus 1 with chitosan and liposome as deliver carrier in ducks.Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastomaTargeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product.Electroporation-based DNA immunisation: translation to the clinic.Would gene therapy for the treatment of male infertility be safe?Expression of B-cell activating factor enhances protective immunity of a vaccine against Pseudomonas aeruginosaSafety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®).Viral gene therapy for breast cancer: progress and challenges.Biodistribution and safety profile of recombinant adeno-associated virus serotype 6 vectors following intravenous delivery.Direct and long-term detection of gene doping in conventional blood samples.Longevity of rAAV vector and plasmid DNA in blood after intramuscular injection in nonhuman primates: implications for gene doping.
P2860
Q28730144-DED3FA8D-903A-42CC-9088-7751AF81EFF6Q34361637-DF0512B9-DC09-4844-A8CB-3D680366E018Q35144415-6B4C1836-53E5-4383-8D9E-C8483E4A7978Q36288916-3A210884-BD4B-431E-B273-28DA1576F678Q36539092-16C127E4-4A03-44E5-9C3A-6F4BB0BB1814Q36741202-C9E130F6-5892-4B18-9780-6CE05469890BQ36811505-6DF5B09E-D599-4497-AB10-E0DB72414A4CQ36953167-878B98F3-3D68-49C5-8FC1-F4995AE2D477Q36981658-BB763F01-A976-42F8-A944-6E2E1C1949E2Q37206432-1D0C54DF-3A45-4A99-8A99-4886728F5C99Q37256524-BC96B714-03C6-46E8-9BF6-32ED8E6F356BQ38168940-09FA5ADF-6053-4695-9A86-32AF0CBF0BB9Q39366114-1083018F-74F9-4BFC-868C-8AA113D1E958Q40091715-123BE4A9-AFDB-4A1A-8AFF-95EAC83FAC4AQ45863287-0DE17F70-2AB3-414D-B519-634BAEF725A7Q45868167-95252141-0983-432E-AABA-D278DC52FF67
P2860
Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Gene transfer vector biodistri ...... ical gene therapy development.
@ast
Gene transfer vector biodistri ...... ical gene therapy development.
@en
type
label
Gene transfer vector biodistri ...... ical gene therapy development.
@ast
Gene transfer vector biodistri ...... ical gene therapy development.
@en
prefLabel
Gene transfer vector biodistri ...... ical gene therapy development.
@ast
Gene transfer vector biodistri ...... ical gene therapy development.
@en
P2860
P356
P1433
P1476
Gene transfer vector biodistri ...... ical gene therapy development.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.GT.3302378
P478
11 Suppl 1
P577
2004-10-01T00:00:00Z